ELAN insider sale via UBS — 49,333 shares on NYSE ($830K)

Rhea-AI Filing Summary

Elanco Animal Health (ELAN) reported a proposed sale of 49,333 shares of common stock through UBS on the NYSE with an aggregate market value of $830,000, representing approximately 0.01% of the 496,646,504 shares outstanding. The filing lists the acquisition history: 1,536 shares on 12/03/2020, 16,738 shares on 02/22/2021, and 31,059 shares on 02/22/2022, all identified as stock awards.

The notice indicates no securities sold in the past three months and includes the signatory's representation that they do not know any material nonpublic information about the issuer. The form references Rule 144 procedures and mentions Rule 10b5-1 plan disclosure but does not provide a plan adoption or instruction date.

Positive

• Sale details fully disclosed: 49,333 shares with aggregate market value of $830,000, broker identified as UBS, and approximate sale date provided (08/11/2025).
• Acquisition history provided: All shares were acquired as stock awards on 12/03/2020, 02/22/2021, and 02/22/2022, totaling the 49,333 shares reported.

Negative

• No Rule 10b5-1 plan date: The filing references trading plans but does not state a plan adoption or instruction date for the sale.
• Limited context on intent: The form does not explain whether the sale is part of a preplanned disposition or for personal/liquidity reasons.

Insights

Securities Analyst

TL;DR Routine insider sale notice: 49,333 shares (~0.01% of outstanding) via UBS; acquisitions were stock awards from 2020–2022.

The Form 144 discloses a proposed sale of 49,333 Elanco common shares with an aggregate market value of $830,000 to be executed through UBS on the NYSE. The filing is specific about acquisition dates and quantities and reports no sales in the prior three months, which supports transparency. Given the size—about 0.01% of outstanding shares—the transaction appears immaterial to company capitalization based on information provided.

Corporate Governance Expert

TL;DR Disclosure is complete on holdings and broker, but the filing omits any Rule 10b5-1 plan adoption date.

The filer documents the source of the shares (stock awards) and the broker executing the sale (UBS), and affirms lack of material nonpublic information. However, the filing does not state whether a Rule 10b5-1 trading plan exists or provide an adoption date or instruction date, which would clarify whether the sale is pre-planned. The absence of recent sales in the prior three months is explicitly reported.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	49333	830000	496646504	08/11/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/22/2021	Stock Award	Issuer			16738	02/22/2021	NA
Common Stock	02/22/2022	Stock Award	Issuer			31059	02/22/2022	NA
Common Stock	12/03/2020	Stock Award	Issuer			1536	12/03/2020	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Elanco (ELAN) Form 144 disclose about the proposed sale?

49,333 common shares proposed for sale via UBS on the NYSE with aggregate market value of $830,000 and approximate sale date 08/11/2025.

When and how were the shares being sold acquired?

All shares were acquired as stock awards: 1,536 on 12/03/2020, 16,738 on 02/22/2021, and 31,059 on 02/22/2022.

Did the filer report any sales of Elanco securities in the past three months?

The filing states Nothing to Report for securities sold during the past three months.

What representation did the seller make about material nonpublic information?

The seller represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.

What class of security and exchange are involved in this filing?

The filing concerns Common Stock of Elanco to be sold on the NYSE.